NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions.
The fund generally is expected to consist of more than 15 companies but not more than 100 companies.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 10.02% |
| ABT | Abbott Laboratories | Healthcare | Medical Devices | 4.79% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.33% |
| RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 4.05% |
| NOVO-B | Novo Nordisk A/S | Healthcare | Biotechnology | 3.94% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 3.55% |
| UNH | UnitedHealth Group Incorporated | Healthcare | Healthcare Plans | 3.51% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 3.49% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 3.47% |
| MDT | Medtronic PLC | Healthcare | Medical Devices | 3.45% |
| BSX | Boston Scientific Corp | Healthcare | Medical Devices | 3.34% |
| TMO | Thermo Fisher Scientific Inc | Healthcare | Diagnostics & Research | 3.30% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 3.17% |
| 0QIU | Novo Nordisk A/S Class B | 3.14% | ||
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 2.86% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 2.68% |
| CRNX | Crinetics Pharmaceuticals Inc | Healthcare | Biotechnology | 2.52% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.48% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 2.36% |
| DHR | Danaher Corporation | Healthcare | Diagnostics & Research | 2.33% |